TATVA · Basic Materials · Specialty Chemicals
Composite scorecard: 46/100 — Quality 47 · Valuation 13 · Momentum 98
| Share price | ₹1,713.70 |
| Market cap | ₹3,103 Cr |
| P/E ratio | 73.5 |
| P/B ratio | 4.0 |
| ROCE | 7.6% |
| Dividend yield | 0.08% |
| Book value | ₹334.03 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹506 Cr | ₹42 Cr | 18.0% |
| 2025 | ₹383 Cr | ₹6 Cr | 9.0% |
| 2024 | ₹394 Cr | ₹30 Cr | 17.0% |
| 2023 | ₹424 Cr | ₹45 Cr | 14.0% |
| 2022 | ₹434 Cr | ₹96 Cr | 25.0% |
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chint